Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: Prospective, observational, multicenter study on 92 cases

Annals of Surgical Oncology

Volumn 20, Issue 6, 2013, Pages 2065-2072

  Duntze, Julien ^a   Litré, Claude Fabien ^a   Eap, Christophe ^a   Théret, Etienne ^a   Debreuve, Adeline ^b   Jovenin, Nicolas ^b,c   Lechapt Zalcman, Emmanuèle ^d   Metellus, Philippe ^e   Colin, Philippe ^f   Guillamo, Jean Sébastien ^d   Emery, Evelyne ^d   Menei, Philippe ^g   Rousseaux, Pascal ^a   Peruzzi, Philippe ^a  

^a HÔPITAL MAISON BLANCHE   (France)

^b Oncocha   (France)

^c INSTITUT JEAN GODINOT   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f Polyclinique Courlancy ^*  (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; ETOPOSIDE; FOTEMUSTINE; IRINOTECAN; TEMOZOLOMIDE;

ABSCESS; ADULT; AGED; ALOPECIA; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL STUDY; COMPUTER ASSISTED RADIOTHERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EFFUSION; EPILEPSY; EXHAUSTION; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LIQUORRHEA; MAJOR CLINICAL STUDY; MENINGITIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; SALVAGE THERAPY; STEROID THERAPY; SUBDURAL EMPYEMA; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG IMPLANTS; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84878255425     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2764-x     Document Type: Article

References (24)

1. Fleury A, Menegoz F, Grosclaude P, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79:1195-202.
2. Laws ER, Parney IF, Huang W, et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467-73.
3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-97.
4. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
5. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet. 1995;345(8956):1008-12.
6. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
7. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008;88:353-7.
8. nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115:3501-11.
9. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33:441-9.
10. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110:583-8.
11. Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J. Neuro-oncology Club of the French Society of Neurosurgery. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol. 2010;17:1740-6.
12. LaRocca RV, Hodes J, Villanueva WG, et al. A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion (abstract TA-28). Neuro Oncol. 2006;8:445.
13. Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs. 2007;21:775-87.
14. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148:269-75; discussion 275.
15. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1994;54:3793-9.
16. Hammond LA, Eckardt JR, Kuhn JG, et al. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res. 2004;10(5):1645-56.
17. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22:4779-86.
18. Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70:101-9.
19. Noël G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (Carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2012;82(2):749-55.
20. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008;24:3239-57.
21. Duntze J, Litré CF, Bajolet O, Theret E, Eap C, Peruzzi P, Rousseaux P. Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature. Neurochirurgie. 2009;55:569-72.
22. Giese A, Bock HC, Kantelhardt SR, Rohde V. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cent Eur Neurosurg. 2010;71:199-206.
23. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15:2887-93.
24. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol. 2000;53(3):220-4.